Health
Immunotherapy after surgery offers recurrence-free survival advantage for patients with high-risk melanoma – News-Medical.Net
Patients with high-risk melanoma who had a course of pembrolizumab after their surgery had a longer time before their disease recurred than patients who got either…
Patients with high-risk melanoma who had a course of pembrolizumab after their surgery had a longer time before their disease recurred than patients who got either ipilimumab or high-dose interferon after surgery. These findings of a large SWOG Cancer Research Network clinical trial, S1404, will be presented at the ASCO annual meeting June 6, 2021.
Researchers also measured overall survival and found no statistically significant difference in overall survival rates between the two groups of patients…
-
Noosa News20 hours agoMoreton Bay oyster farm survives cyclone with help of wave wall innovation
-
Business23 hours ago$10,000 invested in ANZ shares 5 years ago is now worth…
-
Noosa News22 hours agoHelicopter pilots saving lives, providing food and fodder in flooded outback Queensland
-
General21 hours agoInternal Revenue Service starts cutting 20,000 workers